MRNA240920P74000
- 6.00
- +1.64+37.61%
Moderna Newsroom
RBC Capital Reiterates Sector Perform on Moderna, Maintains $75 Price Target
Moderna Analyst Ratings
RBC Capital Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $75
Goldman Sachs Maintains Moderna(MRNA.US) With Buy Rating, Cuts Target Price to $139
Goldman Sachs Maintains Buy on Moderna, Lowers Price Target to $139
Moderna Is Maintained at Overweight by Barclays
Morgan Stanley Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $70
Barclays Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $125
Morgan Stanley Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $70
Jefferies Financial lowers the target price and rating for Moderna.
jpmorgan lowers the target price of moderna to $70.
Brookline Capital Maintains Moderna(MRNA.US) With Buy Rating, Cuts Target Price to $238
Moderna Continues to Decline as Oppenheimer Latest to Downgrade
Moderna Is Maintained at Hold by TD Cowen
BofA Securities Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $110
Moderna Cut to Underweight From Neutral by JP Morgan
Moderna Price Target Cut to $70.00/Share From $88.00 by JP Morgan
A Quick Look at Today's Ratings for Moderna(MRNA.US), With a Forecast Between $94 to $125
Piper Sandler Maintains Overweight on Moderna, Lowers Price Target to $115
Moderna Analyst Ratings